Today

Agents

Chat

Arena

Discover

More

App

The Chemours Company: UBS cuts target price to $15 from $16

CC•2026-11-04

UBS cut its target price for The Chemours Company to $15 from $16.

Related News

N

Novo hikes outlook again as it speeds up Wegovy pill rollout

NVO•2026-11-04

Karyopharm reports sustained benefit through 48 weeks in Phase 3 selinexor myelofibrosis trial

KPTI•2026-11-04

Qualcomm signs major 5G infrastructure deal with SpaceX for Starlink Mobile network

SPCX•2026-11-04

Canadian dollar strengthens, benchmark yield slips

TLT•2026-11-04

Geron says new analyses support RYTELO dosing in lower-risk myelodysplastic syndromes

GERN•2026-11-04

The Chemours Company: UBS cuts target price to $15 from $16 - CC News | Rallies